Roche Reports Strong Sales Growth In The First Quarter Of 2015
Basel, 22 April 2015
• Group sales up 5% at constant exchange rates (CER)1, 3% in Swiss francs
• Pharmaceuticals Division sales up 4%: strong growth in oncology (HER2-positive breast cancer medicines, Avastin, MabThera/Rituxan) and immunology (Actemra/RoActemra, Xolair)
• Second FDA Breakthrough Designation for cancer immunotherapy medicine, anti-PDL1
Help employers find you! Check out all the jobs and post your resume.
• Group sales up 5% at constant exchange rates (CER)1, 3% in Swiss francs
• Pharmaceuticals Division sales up 4%: strong growth in oncology (HER2-positive breast cancer medicines, Avastin, MabThera/Rituxan) and immunology (Actemra/RoActemra, Xolair)
• Second FDA Breakthrough Designation for cancer immunotherapy medicine, anti-PDL1
Help employers find you! Check out all the jobs and post your resume.